VAXICAN
VAXiCAN develops cancer vaccines that train the immune system to attack tumors. Their enveloped virus-like particle platform delivers antigens via engineered oncolytic viruses to stimulate potent immune responses. In-house ML and AI design elements optimize vaccines targeting HER2- and GD2-positive cancers, including breast cancer and neuroblastoma. Pre-clinical programs explore multiple indications with potential first-in-class candidates and collaborations in sequencing with Oxford Nanopore. The company operates as a biotech platform serving researchers and biopharma partners with its vaccine technology and genomic analysis capabilities.
VAXICAN
VAXiCAN develops cancer vaccines that train the immune system to attack tumors. Their enveloped virus-like particle platform delivers antigens via engineered oncolytic viruses to stimulate potent immune responses. In-house ML and AI design elements optimize vaccines targeting HER2- and GD2-positive cancers, including breast cancer and neuroblastoma. Pre-clinical programs explore multiple indications with potential first-in-class candidates and collaborations in sequencing with Oxford Nanopore. The company operates as a biotech platform serving researchers and biopharma partners with its vaccine technology and genomic analysis capabilities.